← Patent Expiry Watch
October 18, 2026 · Patent expires June 25, 2045
AXTLE (PEMETREXED DIPOTASSIUM): The June 25, 2045 Generic Opportunity Window
AXTLE (PEMETREXED DIPOTASSIUM) core drug-substance patent expires on June 25, 2045. Zero generic (ANDA) approvals exist for this active ingredient as of October 18, 2026. No exclusivity grants confirmed. No real litigation signal found.
What we do
We track expirations like this continuously
This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.